Literature DB >> 34107195

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Roland Meisel1.   

Abstract

Entities:  

Year:  2021        PMID： 34107195     DOI： 10.1056/NEJMc2103481

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  1 in total

Review 1.  A glance at the application of CRISPR/Cas9 gene-editing technology in cardiovascular diseases.

Authors:  Neda Roshanravan; Helda Tutunchi; Farzad Najafipour; Mohammadreza Dastouri; Samad Ghaffari; Alireza Jebeli
Journal:  J Cardiovasc Thorac Res       Date:  2022-06-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.